A total of $343 million in private capital was invested in five key biotechnology/therapeutics initiatives for the week ending January 24.
The firms involved were some of the usual suspects with life sciences investors scrambling to help advance gene editing techniques and treatments for cancer and rare diseases.
Hedge fund firm Citadel’s Surveyor Capital participated in two of this past week’s deals, backing Verve Therapeutics and Vera Therapeutics. Set up in 2008, the firm is a global, multi-manager equities strategy and is one of Citadel’s three fundamental equities business.
Continue ReadingUnlock this article instantly, along with the rest of our premium content and daily, weekly and monthly newsletters. We offer pay-as-you-go monthly subscriptions and discounted annual subscriptions with additional benefits: access to Alternatives Watch Research articles and our Annual Investor Compendium.
